[A21-43] Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114
Last updated 20.05.2021
Project no.:
A21-43
Commission:
Commission awarded on 07.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Patients with 5q spinal muscular atrophy (SMA)
Patients with early onset of disease (infantile form, SMA type 1): indication of major added benefit.
Patients with later onset of disease (SMA type 2, type 3 and type 4): added benefit not proven.
Pre-symptomatic patients with 5q SMA: hint of non-quantifiable added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-114 | Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.